Inovio Pharmaceuticals P/E Ratio

Inovio Pharmaceuticals (INO) currently reports a P/E ratio of -1.0. That is below the Industrials sector average of 28.45. Use the charts on this page to explore Inovio Pharmaceuticals's P/E ratio history and peer comparisons.

Inovio Pharmaceuticals's P/E ratio of -1.0 is lower than the Industrials sector average of 28.45. That is roughly 103.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Inovio Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At -1.0, INO can look expensive or cheap only in context — versus its own history, growth rate, and Industrials peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -1.0, then check the historical chart for trend and the peer comparison chart for relative positioning. The Industrials average is 28.45. From there, open related valuation or income-statement pages for Inovio Pharmaceuticals, and consider following INO for alerts when major investors trade the stock.

Inovio Pharmaceuticals is classified in the Industrials sector. On P/E ratio, it currently shows -1.0 versus a sector average near 28.45. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing INO with unrelated industries.